“While we share the administration’s goal of lowering drug costs, we remain concerned that the drug negotiation process may do more harm than good for patients with chronic conditions.
Regardless of intent, setting prices for medications could unintentionally limit patient access to medications due to increased utilization management from insurance providers. It may also threaten the innovation and research patients rely on.
We urge policymakers to pursue reforms that will more directly benefit patients, such as PBM reform.”